f you previously had a DRI account, you will need to create a new account for the DRI Online Education Center to register for this program.
Pharmaceutical and medical device manufacturers encounter numerous risks which, if not handled properly, could lead to litigation. Risks include the challenges of properly marketing products, complying with numerous regulations and emerging adverse events. Mass tort litigation, and challenges based on the False Claims Act and the Antikickback Statute among others, pose perpetual risks along with handling the erosion of time tested defenses such as the learned intermediary doctrine. With an ever-shifting tide, it is important to stay current on these topics. Register now to learn from top attorneys whose focus is watching for and defending against these risks.
Who Should Attend
What You Will Learn
Samuel J. Abate, Jr. is a partner in Pepper Hamilton’s New York office. Mr. Abate focuses his practice in civil litigation, with an emphasis on the defense of pharmaceutical and medical device companies in complex litigation involving marketed products and medical devices. He also advises clients on issues relating to electronic discovery.
Mark C. Hegarty is a partner in Shook Hardy & Bacon’s Kansas City office. His practice is focused on nationwide complex litigation, including the defense of pharmaceutical and medical device manufacturers. Mr. Hegarty has spoken on numerous occasions regarding various litigation topics, including at DRI’s Drug and Medical Device’s Annual Seminar.
Allison M. Brown is a partner in Weil, Gotshal & Manges’ Princeton office. Ms. Brown has extensive experience in complex litigation, including commercial, environmental, pharmaceutical product liability, and mass tort actions. She also served as trial counsel in a high-profile antitrust case to block a multi-billion dollar merger between two companies.
DRI, The Voice of the Defense Bar, intends to comply with all applicable anti trust laws. Accordingly, DRI cannot, and will not, tolerate conduct that could lead to, or even suggest, agreement among its members that might restrain trade or violate such laws. All such conduct is a violation of DRI policy